-- Mary Elizabeth Dallas
WEDNESDAY, July 2, 2014 (HealthDay News) -- Although recent
research has linked testosterone therapy with a higher risk for
heart attack and stroke, a new study involving more than 25,000
older men suggests otherwise.
The study, funded by the U.S. National Institutes of Health, may
help ease some fears about testosterone therapy for patients and
their families, the study authors said.
"Our investigation was motivated by a growing concern, in the U.S. and internationally, that testosterone therapy increases men's risk for cardiovascular disease, specifically heart attack and stroke," lead researcher Jacques Baillargeon, an associate professor of epidemiology at the University of Texas Medical Branch at Galveston, said in a university news release.
"This concern has increased in the last few years based on the results of a clinical trial and two observational studies," he said. "It is important to note, however, that there is a large body of evidence that is consistent with our finding of no increased risk of heart attack associated with testosterone use."
According to background information supplied by the researchers,
the market for testosterone has grown significantly in recent
years. Every year, $1.6 billion is spent on these products, with
the aim of boosting muscle tone and sex drive for men with
so-called "low T."
However, investigations into the safety of testosterone therapy
have revealed conflicting results, Baillargeon's team said. Some
studies suggested testosterone was tied to a higher risk of heart
For example, as reported in January by
HealthDay, one study looked at the medical records of 56,000
American men who were prescribed testosterone supplements.
The research, published in the journal
PLoS One, tracked the men for 90 days after they started the
therapy. The study found that heart attack risk doubled for men
over 65 once they were taking the supplements. The same effect was
found in testosterone supplement users who were younger than 65 but
had a history of heart disease. No such effect was seen for men
under 65 years of age without a history of heart disease, the
And on June 20, the U.S. Food and Drug Administration announced
that testosterone supplement products must now carry a warning
label on the general risk of blood clots in the veins. The FDA is
also engaged in an ongoing investigation into the risk of stroke,
heart attack and death in those taking testosterone products.
To further explore this issue, the Galveston team of researchers
examined data collected on more than 25,000 men over the age of 65.
The men, who were all Medicare beneficiaries, received testosterone
therapy for up to eight years.
The study also included a "control group" of similar men who
were not treated with testosterone therapy.
The findings, which were published July 2 in the
Annals of Pharmacotherapy, found that testosterone therapy
was not linked with any increased risk for heart attack. In fact,
men at greater risk for heart problems who used testosterone
actually had a lower rate of heart attacks than similar men who did
not receive this treatment, the researchers said.
"This is a rigorous analysis of a large number of patients," noted Baillargeon. "Our findings did not show an increased risk of heart attack associated with testosterone use in older men," he said.
Still, the issue is probably far from settled, Baillargeon
"Large scale, randomized clinical trials will provide more definitive evidence regarding these risks in the coming years," he said.
The Urology Care Foundation has more about
low testosterone and testosterone therapy.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.